uniQure wins a BTD for hemophilia B therapy; Allergan scores sNDA for Avycaz
• The Dutch biotech uniQure has picked up a breakthrough drug designation from the FDA for AMT-060, its gene therapy for hemophilia B. Spark …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
